Please upgrade your browser.
A marker for diagnosis, prognosis and treatment
Join your friends from the Kidney Cancer Association for SU2C from Hollywood, September 7, 2012
The decades of research into the various molecular mechanistic pathways that cause the constellation of diseases known as âcancerâ have produced literally hundreds of new, exciting experimental medicines.
Children with kidney cancer were most at risk of developing diabetes, with 14.7 percent of those treated with radiation diagnosed with the condition by age 45, the study found.
Novartis, the Swiss pharmaceutical company, will appear before the Indian Supreme Court Wednesday to appeal against a patent rejection for a popular cancer drug. A decision in favor of the company could have a devastating impact on cheap supplies of many kinds of generic drugs for poor patients.
New Move Could Identify More Than 800,000 People With Hepatitis C
Computers may give new life to old medicines
Cellceutix Corp announced that it has entered into an agreement with Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School, on a research project with Kevetrin.
Intrigued by those results, the Duke researchers used data from the trial to determine whether a high LDH level was more than just a prognostic tool in advanced kidney cancer, and could perhaps also predict the effectiveness of an mTOR inhibitor.
Researchers from the University of Chicago Medicine said the combination could help patients avoid side effects associated with high doses of the drug and reduce the cost of the medication.
|NeonCRM by Neon One|